Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Factor XI deficiency

P H Bolton-Maggs1

  • 1Royal Liverpool Children's Hospital NHS Trust, Alder Hey, UK.

Bailliere'S Clinical Haematology
|June 1, 1996
PubMed
Summary
This summary is machine-generated.

Factor XI deficiency causes bleeding disorders, particularly in Ashkenazi Jews. Understanding its role in coagulation is crucial for managing bleeding risks during surgery.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

International haemovigilance: what have we learned and what do we need to do next?

Transfusion medicine (Oxford, England)·2019
Same author

A cross-reactive material positive variant of coagulation factor XI (FXIP520L) with a catalytic defect.

Journal of thrombosis and haemostasis : JTH·2007
Same author

Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study.

Lancet (London, England)·2002
Same author

The nontreatment of childhood ITP (or "the art of medicine consists of amusing the patient until nature cures the disease").

Seminars in thrombosis and hemostasis·2001
Same author

The diagnosis and management of hereditary spherocytosis.

Bailliere's best practice & research. Clinical haematology·2000
Same author

Factor XI deficiency and its management.

Haemophilia : the official journal of the World Federation of Hemophilia·2000
Same journal

Current status of stem cell therapy and prospects for gene therapy for the disorders of globin synthesis.

Bailliere's clinical haematology·2000
Same journal

Pharmacological therapy.

Bailliere's clinical haematology·2000
Same journal

Prenatal diagnosis and screening of the haemoglobinopathies.

Bailliere's clinical haematology·2000
Same journal

Sickle cell disease: clinical management.

Bailliere's clinical haematology·2000
Same journal

Pathophysiology of sickle cell disease.

Bailliere's clinical haematology·2000
Same journal

Thalassaemia: clinical management.

Bailliere's clinical haematology·2000
See all related articles

Area of Science:

  • Hematology
  • Coagulation Science

Background:

  • Factor XI is essential for normal blood coagulation, as evidenced by bleeding in deficient patients.
  • Thrombin activation of factor XI has refined coagulation models.
  • Factor XI deficiency disproportionately affects Ashkenazi Jews.

Purpose of the Study:

  • To elucidate the role of factor XI in hemostasis.
  • To review the clinical presentation and genetic basis of factor XI deficiency.
  • To discuss therapeutic strategies for factor XI deficient patients.

Main Methods:

  • Review of existing literature on factor XI function and deficiency.
  • Analysis of genetic mutations associated with factor XI deficiency.
  • Evaluation of therapeutic options and their associated risks.

Related Experiment Videos

Main Results:

  • Factor XI deficiency leads to bleeding, often provoked by surgery, with variable severity.
  • Two specific mutations account for most factor XI deficiency in Ashkenazi Jews.
  • Factor XI concentrate use carries risks of thrombosis; fresh frozen plasma is an alternative.

Conclusions:

  • Factor XI plays a critical role in hemostasis, and its deficiency presents a variable bleeding risk.
  • Genetic factors, particularly in the Ashkenazi population, are key to understanding deficiency.
  • Cautious use of factor XI concentrate is advised, with fresh frozen plasma as a potential alternative.